International Business Machines Corporation

Executive Summary

BUY, Medium conviction. IBM rates a BUY at Medium conviction. The setup is no longer about a clean near-term beat story after management cut FY26 revenue growth to 4%-5%, but the stock has already reset hard, down 30.9% from the high and 11.4% below the 200-day average, while free cash flow guidance was maintained and some slipped software deals have already closed in Q3. At 20.05x earnings, the stock is not optically cheap on trailing numbers, but the case rests on better forward earnings power than FY2025 suggests as software mix, productivity, and AI-linked demand improve.

Investment Thesis

IBM is interesting here because the stock is no longer priced for a clean transformation story. It is priced after a disappointment. Management admitted, "As you saw in our pre-announcement, our second quarter performance fell short of expectations." The company then cut FY26 revenue growth to 4%-5% from prior 5%+ framing, reduced software growth to 6%-8%, and posted a weak 17.3% Q2 EBITDA margin. That reset matters because the stock is now 30.9% below the $332.46 high and 11.4% below its 200-day average. The market has already punished the near-term miss.

The buy case depends on three things. First, the software shortfall has to be mostly timing, not lost demand. Management said roughly 1/3 of slipped deals already closed in the first three weeks of Q3, which is a tangible data point, not hand-waving. Second, the strategic assets have to keep outgrowing the company average. Red Hat at 11% growth and ARR at $24.6B, up 8%, suggest the better part of IBM is still moving. Consulting is not dead either, with signings up 6% and GenAI making up about 50% of signings and over 30% of backlog. Third, productivity has to flow through. IBM maintained a free cash flow growth target of about $1B and still expects 100 bps of operating pretax margin expansion, despite the revenue reset.

What the market may be mispricing is the gap between reported FY2025 economics and normalized earnings power. FY2025 looked ugly, with operating margin at 5.6% versus 16.1% in the prior year and EPS down 27.5% to $11.36. If that margin profile were the new normal, the stock would not be attractive at 20.05x earnings. But if FY2025 was the trough created by mix, delayed software conversion, and infrastructure weakness, then trailing valuation is overstating the true multiple on forward earnings.

Conviction stays at Medium because the balance sheet is not forgiving. $65.3B of debt, 1.89 debt/equity, 3.78x debt/EBITDA, and a 0.79 current ratio leave less room for another stumble. This is not a heroic upside story. It is a recovery and execution story. At today's price, that is enough for a BUY, but not enough for high conviction until Q3 confirms the software catch-up and margin repair.

Key Metrics

Financial Strength

IBM's financial profile is mixed. The positive is that management maintained FY26 free cash flow growth of about $1B even after the Q2 miss, and the company still has room to improve margins through productivity actions rather than relying only on demand. The negative is that the balance sheet is stretched for a company growing revenue just 1.1% in FY2025, with $65.3B of debt, 3.78x debt/EBITDA, and a 0.79 current ratio. That leverage does not look dangerous in an immediate solvency sense, but it raises the cost of being wrong on the recovery thesis, especially with the 10-year Treasury at 4.94% and a market less willing to ignore execution slips.

Competitive Position

IBM still has a real enterprise moat, but it is narrower and more segment-specific than the headline brand suggests. The durable pieces are Red Hat, mission-critical software, deep installed relationships with large regulated enterprises, and the ability to wrap consulting around technology transitions customers cannot execute alone. That moat is holding up best where workloads are sticky and hybrid, which is consistent with 11% Red Hat growth and $24.6B of ARR. The weaker flank is infrastructure, where revenue fell 7% and Z underperformed internal expectations, showing that not every legacy franchise can fund the future indefinitely.

Management & Guidance

Management's FY26 guidance is lower, but not broken. The company now expects revenue growth of 4%-5%, software growth of 6%-8%, and 100 bps of operating pretax margin expansion, while keeping the free cash flow growth target at about $1B. Credibility is helped by an 8-quarter EPS beat-or-meet streak and by the fact that management provided a specific recovery datapoint, with about 1/3 of slipped Q2 deals already closed in early Q3. Credibility is hurt by the need to cut the outlook after saying the business was tracking better earlier in the year, and by the sharp Q2 profitability deterioration. Net result: guidance is investable, but not bankable.

Bull Case

• Management maintained FY26 free cash flow growth of about $1B despite cutting revenue growth, which matters because the market usually punishes IBM more for cash flow slippage than for one quarter of delayed software closures.
• Execution credibility is decent: IBM has beaten or met EPS in 8 straight quarters, including +12.7%, +8.2%, +5.7%, +5.5%, and +4.9% beats before the July quarter landed only in line.
• The software and platform pieces are healthier than the headline miss implies: Red Hat accelerated to 11% growth, recurring software held up, and ARR reached $24.6B, up 8% year over year.
• There is real self-help on margins even after a bad quarter: FY26 operating pretax margin is still guided to expand 100 bps, supported by AI-led software development, sales efficiency, and supply-chain productivity.

Bear Case

• FY2025 earnings quality was weak: revenue rose only 1.1% to $67.5B, EPS fell 27.5% to $11.36, and operating margin collapsed to 5.6% from 16.1% the prior year.
• Q2 exposed how fragile mix still is: EBITDA margin was 17.3%, down 240 bps from Q1 and 850 bps from prior-year Q2, while operating gross margin fell 70 bps on the revenue shortfall and mix.
• Balance-sheet flexibility is limited for a company with modest growth, with $65.3B of debt, 3.78x debt/EBITDA, 1.89 debt/equity, and a 0.79 current ratio.
• Valuation is not a layup: IBM trades at 20.05x earnings versus a 19.6x peer average and 3.12x sales versus 3.1x peers, so the market is already paying roughly peer multiples for a business that just cut guidance.

Valuation & Price Target

Engine price target $231.12 (+0.7% vs current), High confidence.

• P/E Multiple: $231.24 (28% weight)
• P/S Multiple: $182.25 (20% weight)
• Quality-adjusted: $247.96 (20% weight)
• DCF: $311.45 (8% weight)

The quant baseline is HOLD with a $231.12 price target, only 0.7% above the current price, and that caution is understandable given the guidance cut, 17.3% Q2 EBITDA margin, and leverage at 3.78x debt/EBITDA. The divergence to BUY rests on time horizon and normalization: the quant target is anchored to near-term blended valuation, while the stock has already derated to -30.9% from the high even as FY26 free cash flow guidance was maintained, Red Hat accelerated to 11%, ARR reached $24.6B, and management still expects 100 bps pretax margin expansion. Sell-side consensus remains Strong Buy at 11 buy / 3 hold / 1 sell, but that is low-signal context only; the real issue is whether Q2 was a timing air pocket or a structural slowdown. The rating assumes timing, with enough evidence from Q3 closures to lean positive, but only at Medium conviction.

Risk Assessment

Risk score 44/100 (Moderate). The biggest risk is that Q2 software deal slippage proves to be demand weakness rather than timing, which would pressure a stock at 20.05x earnings with only 4%-5% FY26 revenue growth guidance and a leveraged balance sheet at 3.78x debt/EBITDA.

The Bottom Line

IBM rates a BUY at Medium conviction. The stock is not cheap enough for complacency and the quant framework is right to flag limited near-term upside, but the market looks too focused on a single quarter's slippage and not focused enough on recovering software conversion, Red Hat momentum, and margin self-help. This is a recovery story, not a momentum story, and the October 21 report needs to confirm it. A move back toward cleaner execution with maintained free cash flow would support upside over the next 1-2 years. The view would turn less positive if Q3 fails to show software catch-up, or if free cash flow guidance slips from the planned roughly $1B year-over-year increase.